Stacey A Kenfield1, Natalie DuPre2, Erin L Richman3, Meir J Stampfer4, June M Chan5, Edward L Giovannucci4. 1. Department of Urology, University of California, San Francisco, San Francisco, CA, USA; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA. Electronic address: KenfieldS@urology.ucsf.edu. 2. Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA. 3. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA. 4. Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Nutrition, Harvard School of Public Health, Boston, MA, USA. 5. Department of Urology, University of California, San Francisco, San Francisco, CA, USA; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Abstract
BACKGROUND: Prostate cancer (PCa) mortality rates are lower in the Mediterranean countries compared with northern Europe. Although specific components of the Mediterranean diet (Med-Diet) may influence PCa risk, few studies have assessed the traditional Med-Diet pattern with the risk of incident advanced or lethal PCa or with disease progression among men diagnosed with nonmetastatic PCa. OBJECTIVE: To determine whether the traditional Med-Diet pattern is associated with risk of incident advanced or lethal PCa and with PCa-specific and overall mortality among men with PCa. DESIGN, SETTING, AND PARTICIPANTS: We prospectively followed 47 867 men in the Health Professionals Follow-up Study followed from 1986 to 2010. The case-only analysis included 4538 men diagnosed with nonmetastatic PCa, followed from diagnosis to lethal outcome or to January 2010. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We used Cox proportional hazards models to examine traditional and alternative Med-Diet scores in relation to PCa incidence outcomes (advanced and lethal disease). In a case-only survival analysis, we examined postdiagnostic Med-Diet and risk of lethal (metastases or PCa death) and fatal PCa as well as overall mortality among men diagnosed with nonmetastatic disease. RESULTS AND LIMITATIONS: Between 1986 and 2010, 6220 PCa cases were confirmed. The Med-Diet was not associated with risk of advanced or lethal PCa. In the case-only analysis, there was no association between the Med-Diet after diagnosis and risk of lethal or fatal PCa. However, there was a 22% lower risk of overall mortality (hazard ratio: 0.78; 95% confidence interval, 0.67-0.90; p(trend)=0.0007) among men with greater adherence to the Med-Diet after PCa diagnosis. We found similar associations for the alternative score. CONCLUSIONS: A higher Med-Diet score was not associated with risk of advanced PCa or disease progression. Greater adherence to the Med-Diet after diagnosis of nonmetastatic PCa was associated with lower overall mortality.
BACKGROUND:Prostate cancer (PCa) mortality rates are lower in the Mediterranean countries compared with northern Europe. Although specific components of the Mediterranean diet (Med-Diet) may influence PCa risk, few studies have assessed the traditional Med-Diet pattern with the risk of incident advanced or lethal PCa or with disease progression among men diagnosed with nonmetastatic PCa. OBJECTIVE: To determine whether the traditional Med-Diet pattern is associated with risk of incident advanced or lethal PCa and with PCa-specific and overall mortality among men with PCa. DESIGN, SETTING, AND PARTICIPANTS: We prospectively followed 47 867 men in the Health Professionals Follow-up Study followed from 1986 to 2010. The case-only analysis included 4538 men diagnosed with nonmetastatic PCa, followed from diagnosis to lethal outcome or to January 2010. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We used Cox proportional hazards models to examine traditional and alternative Med-Diet scores in relation to PCa incidence outcomes (advanced and lethal disease). In a case-only survival analysis, we examined postdiagnostic Med-Diet and risk of lethal (metastases or PCa death) and fatal PCa as well as overall mortality among men diagnosed with nonmetastatic disease. RESULTS AND LIMITATIONS: Between 1986 and 2010, 6220 PCa cases were confirmed. The Med-Diet was not associated with risk of advanced or lethal PCa. In the case-only analysis, there was no association between the Med-Diet after diagnosis and risk of lethal or fatal PCa. However, there was a 22% lower risk of overall mortality (hazard ratio: 0.78; 95% confidence interval, 0.67-0.90; p(trend)=0.0007) among men with greater adherence to the Med-Diet after PCa diagnosis. We found similar associations for the alternative score. CONCLUSIONS: A higher Med-Diet score was not associated with risk of advanced PCa or disease progression. Greater adherence to the Med-Diet after diagnosis of nonmetastatic PCa was associated with lower overall mortality.
Authors: Edward Giovannucci; Eric B Rimm; Yan Liu; Meir J Stampfer; Walter C Willett Journal: J Natl Cancer Inst Date: 2002-03-06 Impact factor: 13.506
Authors: Kim T B Knoops; Lisette C P G M de Groot; Daan Kromhout; Anne-Elisabeth Perrin; Olga Moreiras-Varela; Alessandro Menotti; Wija A van Staveren Journal: JAMA Date: 2004-09-22 Impact factor: 56.272
Authors: Erin L Richman; Stacey A Kenfield; Jorge E Chavarro; Meir J Stampfer; Edward L Giovannucci; Walter C Willett; June M Chan Journal: JAMA Intern Med Date: 2013-07-22 Impact factor: 21.873
Authors: Edward Giovannucci; Eric B Rimm; Yan Liu; Meir J Stampfer; Walter C Willett Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-12 Impact factor: 4.254
Authors: Meng Yang; Stacey A Kenfield; Erin L Van Blarigan; Julie L Batista; Howard D Sesso; Jing Ma; Meir J Stampfer; Jorge E Chavarro Journal: Cancer Prev Res (Phila) Date: 2015-06
Authors: Antonella Zucchetto; Andrea Gini; Nitin Shivappa; James R Hébert; Carmen Stocco; Luigino Dal Maso; Silvia Birri; Diego Serraino; Jerry Polesel Journal: Int J Cancer Date: 2016-06-11 Impact factor: 7.396
Authors: Lixin Song; Ting Guan; Peiran Guo; Thomas C Keyserling; Courtney Van Houtven; Xianming Tan Journal: J Cancer Surviv Date: 2019-08-22 Impact factor: 4.442
Authors: Meng Yang; Stacey A Kenfield; Erin L Van Blarigan; Kathryn M Wilson; Julie L Batista; Howard D Sesso; Jing Ma; Meir J Stampfer; Jorge E Chavarro Journal: Int J Cancer Date: 2015-06-03 Impact factor: 7.396
Authors: Brandy-Joe Milliron; Michael Bruneau; Elias Obeid; Laura Gross; Lisa Bealin; Christa Smaltz; Veda N Giri Journal: Prostate Date: 2019-03-24 Impact factor: 4.104
Authors: Benjamin C Fu; Fred K Tabung; Claire H Pernar; Weike Wang; Amparo G Gonzalez-Feliciano; Ilkania M Chowdhury-Paulino; Steven K Clinton; Edmund Folefac; Mingyang Song; Adam S Kibel; Edward L Giovannucci; Lorelei A Mucci Journal: Eur Urol Date: 2021-01-06 Impact factor: 20.096